Skip to content
GHIAA Logo Small
Envelope
Linkedin-in
Twitter
  • Home
  • Our Work
    • GHIAA
    • MAPGuide
  • About
    • About GHIAA
    • Team
  • News
  • Resources
    • Useful Links
    • COVID19
  • Contact
  • search
Menu
  • Home
  • Our Work
    • GHIAA
    • MAPGuide
  • About
    • About GHIAA
    • Team
  • News
  • Resources
    • Useful Links
    • COVID19
  • Contact
  • search
 
search

License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).

License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).

License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

MPP License Agreement with Gilead

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading MPP License Agreement with Gilead

Funder Development Partnering Agreement

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue Reading Funder Development Partnering Agreement

Lambert Agreement D

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue Reading Lambert Agreement D

License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue Reading License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue Reading License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
  • 1
  • 2
  • Go to the next page

Recent Posts

  • MAPGuide Glossary (DRAFT)
  • Key Terms of Alliance Agreements

Recent Comments

    Archives

    • May 2020

    Categories

    • Resource & Analysis

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Tweets by GHIAAteam

    GHIAA Supporters

    Special thanks to our supporters at Duke Law School Community Enterprise Clinic

    If you are interested in providing funding or an in-kind contribution to support GHIAA’s work, please contact us using the form below.  

    Global Health Innovation Alliance Accelerator is a 501(c)(3) non-profit recognized by the IRS.

    Contact Us

    Get In Touch

    info@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    Our Work
    MAPGuide
    About GHIAA
    Team
    News
    Useful Links
    COVID19

    Contact Us

    Get In Touch

    info@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    GHIAA
    MAPGuide
    About GHIAA
    Team
    News
    Links
    COVID19

     

    Twitter
    Linkedin-in

    info@ghiaa.org

    Privacy Policy

    • Privacy Policy
    • Join
    Menu
    • Privacy Policy
    • Join

    © 2021 Global Health Innovation Alliance Accelerator. All Rights Reserved

    Close Menu

    Sign Up to Our Newsletter

    Receive updates about GHIAA’s latest tools, resources and news.

    I consent to receiving email updates from GHIAA and have read and agree to the Privacy Policy and Terms of Service..

    Select Technology

    • Any Technologies
    • Device
    • Diagnostic
    • Drug
    • Vaccine

    Select Partner Type

    • Any Partner types
    • Academic institution
    • Biotechnology company
    • Contract research organization
    • Funder
    • General Industry
    • Government
    • Multilateral organization
    • Multinational pharmaceutical company
    • Other nonprofit
    • Pharmaceutical manufacturer
    • Product development partnership
    • Vaccine manufacturer

    Select Development Stage

    • Any Develoment stages
    • Discovery/Concept
    • Preclinical
    • Early clinical (through Phase 2)
    • Late clinical (Phase 3)
    • Commercialization
    • Field Testing

    Select Issue or Sub-issues

    • Access to medicines
      • All Access to medicines
      • Equitable access
      • Funder step-in rights
      • Outbreak preparedness
      • Pandemic Products
      • Policy considerations
      • Affordable or reasonable pricing
      • Public health licenses
      • Supply/Purchase of Products
    • Annexes
      • All Annexes
      • Commercialization strategy
      • Global access plans
      • Regulatory strategy
    • Business model
      • All Business model
      • Benefit/revenue sharing
      • Risk sharing
      • Royalties & payments
    • Consortium structure & management
      • Consortium structure & management
    • Information sharing & data safety
      • All Information sharing & data safety
      • Confidentiality
      • Data management
      • Exceptions and limitations to the confidentiality obligations
      • Information sharing
      • Material transfer
      • Technology transfer
    • IP ownership & licensing
      • All IP ownership & licensing
      • Access to results
      • Exceptions or limitations to the IP ownership rules
      • Exploitation of results
      • Ownership of background IP
      • Ownership of results
      • Protection of results
      • Sublicenses
      • Use of background IP
    • Liability
      • All Liability
      • Indemnity / indemnification
      • Insurance
      • Limitation of liability/damage
      • Warranties
    • Open sciences & open data
      • All Open sciences & open data
      • Data & material sharing
      • Open data
      • Open sciences
      • Publication
    • Other
      • All Other
      • Conflict of Interest
      • Dispute resolution
      • Reporting
      • Survival
    • Term & termination
      • All Term & termination
      • Effect of termination
      • Term of agreement
      • Termination & withdrawal